Patient characteristics (N = 32)
| Characteristic . | Value . |
|---|---|
| Median age (range) | 57 (23-67) |
| Age <60 | 21 (66%) |
| Age <50 | 11 (34%) |
| Median KPS (range) | 80 (40-100) |
| KPS <70 | 6 (19%) |
| KPS <50 | 1 (3%) |
| Women | 15 (47%) |
| Men | 17 (53%) |
| MSK RPA | |
| Class I | 11 (34%) |
| Class II | 15 (47%) |
| Class III | 6 (19%) |
| DLBCL | 32 (100%) |
| CSF cytology* | |
| Positive | 1 (3%) |
| Suspicious | 2 (6%) |
| Not performed | 1 (3%) |
| Ocular involvement | 3 (9%) |
| Median product of tumor diameters (range) | 6 cm2 (0-20 cm2) |
| Characteristic . | Value . |
|---|---|
| Median age (range) | 57 (23-67) |
| Age <60 | 21 (66%) |
| Age <50 | 11 (34%) |
| Median KPS (range) | 80 (40-100) |
| KPS <70 | 6 (19%) |
| KPS <50 | 1 (3%) |
| Women | 15 (47%) |
| Men | 17 (53%) |
| MSK RPA | |
| Class I | 11 (34%) |
| Class II | 15 (47%) |
| Class III | 6 (19%) |
| DLBCL | 32 (100%) |
| CSF cytology* | |
| Positive | 1 (3%) |
| Suspicious | 2 (6%) |
| Not performed | 1 (3%) |
| Ocular involvement | 3 (9%) |
| Median product of tumor diameters (range) | 6 cm2 (0-20 cm2) |
MSK RPA, Memorial Sloan-Kettering prognostic score determined by recursive partitioning analysis (I, age <50; II, age ≥50 and KPS ≥70; III, age ≥50 and KPS <70).
Conventional cytology; flow cytometry not performed.